77 results
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
that, based on an assessment of the preliminary data from the Phase 3 clinical development program, diazoxide choline may demonstrate substantial improvement
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
. The designation reflects the Agency’s determination that, based on an assessment of the preliminary data from the Phase 3 clinical development program
8-K
EX-1.1
u65d3a
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
k0o5xp
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
o4ba74 2cf6rjg9w
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
w5cc6vfcti 8e2rsi
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
ouvl5kiohi
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
1lns6bspa8 s8i2
16 Aug 23
Departure of Directors or Certain Officers
9:00am
8-K
EX-10.1
go08fw1my8av
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm